Novartis buys Mallinckrodt's FDA voucher for $100M but remains mum on where to use its 7th PRV

Zachary Brennan

Senior Editor

Novartis on Thursday confirmed to Endpoints News that it purchased a priority review voucher from bankrupt pharma company Mallinckrodt, but the Swiss-American multinational company declined …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis buys Mallinckrodt's FDA voucher for $100M but remains mum on where to use its 7th PRV

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

No­var­tis buys Mallinck­rodt's FDA vouch­er for $100M but re­mains mum on where to use its 7th PRV

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Novartis buys Mallinckrodt's FDA voucher for $100M but remains mum on where to use its 7th PRV

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena